What it sells
Veterinary medicine startup
Business model breakdown
Buyer: who owns the budget?
UnverifiedVeterinary clinics and owners; likely pharma/animal-health licensing partners.
Trigger: what makes them buy now?
FIP is often fatal within weeks, no effective vaccine exists and unapproved treatments cost tens of thousands of dollars.
Workflow: what inputs become what output?
Integrated prevention plus testing approach; lead FECV control drug OU-500 identified from Oita University compound library and screened at Kitasato University.
Economics: what it saves and how it charges
UnverifiedPre-revenue drug development; commercialisation via approved product or partnership (not stated).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-02-12 | Seed | — | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.